National Institute of Neurological Disorders and Stroke-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:National Institute of Neurological Disorders and Stroke - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8014347
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:55
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
National Institute of Neurological Disorders and Stroke (NINDS), a subsidiary of National Institutes of Health is a healthcare research institute that conducts and supports research on brain and nervous system disorders. The institute’s clinical research areas include Alzheimer’s disease, brain tumors, developmental disorders stroke, epilepsy, Parkinson’s disease, traumatic brain injury, stem cell research, health disparities research, bioengineering research and autism, among others. Its activities comprise training of investigators in basic and clinical neurosciences, and seeks better understanding, diagnosis, treatment, and prevention of neurological disorders. NINDS’ serves scientists, clinicians, and the public. The Institute collaborates with other NIH components, federal agencies, and with voluntary professional and commercial organizations. NINDS is headquartered in Bethesda, Maryland, the US.

National Institute of Neurological Disorders and Stroke – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
National Institute of Neurological Disorders and Stroke, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
National Institute of Neurological Disorders and Stroke, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
National Institute of Neurological Disorders and Stroke, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
National Institute of Neurological Disorders and Stroke, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
National Institute of Neurological Disorders and Stroke, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
National Institute of Neurological Disorders and Stroke, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
ConverGene Enters into Development Agreement with National Institute of Neurological Disorders and Stroke 11
Geneuro Enters into Agreement with National Institute of Neurological Disorders and Stroke 12
Thrombolytic Science Enters into Agreement with National Institute of Neurological Disorders and Stroke 13
Lixte Biotech Enters into R&D Agreement with National Institute of Neurological Disorders and Stroke 14
Licensing Agreements 15
Cogentis Therapeutics to Enter into Licensing Agreement with National Institute of Neurological Disorders and Stroke, National Institutes of Health, Department of Health and Human Services 15
National Institute of Neurological Disorders and Stroke – Key Competitors 16
National Institute of Neurological Disorders and Stroke – Key Employees 17
National Institute of Neurological Disorders and Stroke – Locations And Subsidiaries 18
Head Office 18
Recent Developments 19
Government and Public Interest 19
Nov 06, 2017: The Wistar Institute Awarded More Than $16.5M in Grants to Fund Cancer & Infectious Disease Research and Training 19
Oct 31, 2017: NIH: Study shows how memories ripple through the brain 21
Oct 26, 2017: Scientists find a role for Parkinson’s gene in the brain 22
Oct 23, 2017: Penn Radiology Researcher Awarded $3.9 Million to Help Develop First Three-Dimensional Digital Atlas of Brain Cells 23
Oct 18, 2017: New insight into how brain cells die in Alzheimer’s disease and FTD 24
Oct 02, 2017: CU Researchers win prestigious $2 million NIH grant for brain study 26
Sep 20, 2017: Immune cells may heal bleeding brain after strokes 27
Sep 07, 2017: NIH awards nearly $100 million for Autism Centers of Excellence program 29
Aug 18, 2017: Nortis Awarded $688K NIH Phase II SBIR Fast Track Grant to Develop Living Model of Human Blood-Brain Barrier 31
Aug 15, 2017: New $1.9M federal grant to fund JAX studies of microbiome’s role in multiple sclerosis 32
Jul 06, 2017: NIH and Collaborators Identify the Genomic Cause for Carey-Fineman-Ziter Syndrome 33
Jun 21, 2017: Researchers uncover genetic gains and losses in Tourette syndrome 35
Jun 20, 2017: BlackThorn Therapeutics to Receive Up to $8 Million in NIH Blueprint Neurotherapeutics Network Funding to Advance Kappa Opioid Receptor Antagonist Program 36
Jan 26, 2017: NIH initiates pilot grant program for innovative neurological research 37
Dec 01, 2016: Castro Announces $5.29M for UTSA Brain Health Research 41
Oct 13, 2016: Recombinetics Awarded Two NIH Grants to Develop Humanized Swine Models of Alzheimer’s Disease and Neurofibromatosis 2 42
Oct 07, 2016: Researchers find novel function for old protein in work that could lead to new ways to protect brain from stroke damage 43
Aug 10, 2016: NIH-funded study supports surgery as treatment for myasthenia gravis 44
Apr 07, 2016: Publication highlights release of muscular dystrophy action plan 46
Mar 07, 2016: Eye cells may use math to detect motion 47
Feb 18, 2016: Surgery and stenting safe, effective lowering long-term risk of stroke 48
Feb 18, 2016: NIH-supported trials test hormonal therapy in older men with low testosterone levels 49
Feb 15, 2016: Mind-Controlled Prosthetic Arm Moves Individual ‘Fingers’ 50
Product News 52
Jun 24, 2016: Manufactured stem cells to advance clinical research 52
Other Significant Developments 53
Feb 04, 2016: New members selected for National Advisory Neurological Disorders and Stroke Council 53
Appendix 55
Methodology 55
About GlobalData 55
Contact Us 55
Disclaimer 55

List of Tables
National Institute of Neurological Disorders and Stroke, Pharmaceuticals & Healthcare, Key Facts 2
National Institute of Neurological Disorders and Stroke, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
National Institute of Neurological Disorders and Stroke, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
National Institute of Neurological Disorders and Stroke, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
National Institute of Neurological Disorders and Stroke, Deals By Therapy Area, 2011 to YTD 2017 9
National Institute of Neurological Disorders and Stroke, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
ConverGene Enters into Development Agreement with National Institute of Neurological Disorders and Stroke 11
Geneuro Enters into Agreement with National Institute of Neurological Disorders and Stroke 12
Thrombolytic Science Enters into Agreement with National Institute of Neurological Disorders and Stroke 13
Lixte Biotech Enters into R&D Agreement with National Institute of Neurological Disorders and Stroke 14
Cogentis Therapeutics to Enter into Licensing Agreement with National Institute of Neurological Disorders and Stroke, National Institutes of Health, Department of Health and Human Services 15
National Institute of Neurological Disorders and Stroke, Key Competitors 16
National Institute of Neurological Disorders and Stroke, Key Employees 17

★海外企業調査レポート[National Institute of Neurological Disorders and Stroke-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Technical University of Denmark:製薬・医療:M&Aディール及び事業提携情報
    Summary Technical University of Denmark (DTU) is an educational and research service provider. The university offers undergraduate programs, graduate programs, PhD programs, BSc programs, MSc programs, guest student services, accommodation services and others. It conducts research programs in the ar …
  • Graphic Packaging Holding Company:企業のM&A・事業提携・投資動向
    Graphic Packaging Holding Company - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Graphic Packaging Holding Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mer …
  • Insurance Australia Group Limited:企業の戦略・SWOT・財務情報
    Insurance Australia Group Limited - Strategy, SWOT and Corporate Finance Report Summary Insurance Australia Group Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • Nagase & Co Ltd (8012):企業の財務・戦略的SWOT分析
    Nagase & Co Ltd (8012) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Dukat dd (LURA-R-A):企業の財務・戦略的SWOT分析
    Dukat dd (LURA-R-A) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • SL Green Realty Corp:企業のM&A・事業提携・投資動向
    SL Green Realty Corp - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's SL Green Realty Corp Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A …
  • IDACORP, Inc.:企業の戦略・SWOT・財務情報
    IDACORP, Inc. - Strategy, SWOT and Corporate Finance Report Summary IDACORP, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Journey Energy Inc (JOY):石油・ガス:M&Aディール及び事業提携情報
    Summary Journey Energy Inc (Journey Energy), a subsidiary of Maples Investments LP, is an oil and gas company that offers exploration, development and production oil and natural gas assets. The company provides horizontal and multi-frac drilling, and secondary recovery methods that helps in acquirin …
  • Zenotech Laboratories Ltd (532039):製薬・医療:M&Aディール及び事業提携情報
    Summary Zenotech Laboratories Ltd (Zenotech) manufactures and markets generic biopharmaceuticals products. It classifies its products into two categories, namely, generic biopharmaceuticals and new biological. The company’s Generic biopharmaceuticals is further sub-divided into generic biological an …
  • Florida State University:製薬・医療:M&Aディール及び事業提携情報
    Summary Florida State University (FSU) is an educational service provider that offers graduation and research services. The university offers graduate, undergraduate, professional degree and master degree programs. It offers educational programs in areas of applied studies, arts and sciences, busine …
  • Gartner, Inc.:企業の戦略・SWOT・財務情報
    Gartner, Inc. - Strategy, SWOT and Corporate Finance Report Summary Gartner, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • United Spirits Ltd:企業のM&A・事業提携・投資動向
    United Spirits Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's United Spirits Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), d …
  • Humana Inc (HUM)-製薬・医療分野:企業M&A・提携分析
    Summary Humana Inc (Humana) is a health and well-being company that offers health insurance and Medicare plans, insurance products, and health and wellness services to healthcare providers, employers, individuals, administrators, government, and the public sector. The company’s Medicare products and …
  • Gland Pharma Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Gland Pharma Ltd (Gland Pharma) is a healthcare products provider that develops and manufactures active pharmaceutical ingredients. The company’s products include injectables, pre filled syringes, vials, ampoules, infusions, ophthalmic solutions, lyophilized vials, dry powders, lyophilized p …
  • Amarin Corp Plc (AMRN)-製薬・医療分野:企業M&A・提携分析
    Summary Amarin Corp Plc (Amarin) is a biopharmaceutical company which develops and commercializes medicines for cardiovascular domain. The company's lead product Vascepa (icosapent ethyl) is a US FDA approved single-molecule prescription capsule used as an adjunct to diet, for the reduction of trigl …
  • Napp Pharmaceuticals Ltd:企業の戦略的SWOT分析
    Napp Pharmaceuticals Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • High Peak Royalties Ltd (HPR):企業の財務・戦略的SWOT分析
    High Peak Royalties Ltd (HPR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Craneware plc (CRW):企業の財務・戦略的SWOT分析
    Summary Craneware plc (Craneware) is a healthcare technology company that provides revenue integrity solutions. The company provides patient engagement, charge capture and pricing; coding integrity, and revenue recovery and retention products, chargemaster tool kit, online reference tool kit, physic …
  • Bdo Unibank Inc:企業の戦略・SWOT・財務分析
    Bdo Unibank Inc - Strategy, SWOT and Corporate Finance Report Summary Bdo Unibank Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Falck Renewables S.p.A. (FKR):企業の財務・戦略的SWOT分析
    Falck Renewables S.p.A. (FKR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆